The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase II immunotherapy trial for stage III and IV melanoma patients.
Adam Irwin Riker
No relevant relationships to disclose
Gabriela R. Rossi
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics (I)
Leonard C Alsfeld
No relevant relationships to disclose
Fiona Denham
No relevant relationships to disclose
Lucinda Tennant
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
William Jay Ramsey
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Charles J. Link
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Marilynn Harrison
No relevant relationships to disclose
Nicholas N. Vahanian
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics